Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Operating Expenses (2018 - 2025)

Inmune Bio (INMB) has disclosed Operating Expenses for 8 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 42.18% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.4 million through Dec 2025, up 11.22% year-over-year, with the annual reading at $47.4 million for FY2025, 11.22% up from the prior year.
  • Operating Expenses hit $5.5 million in Q4 2025 for Inmune Bio, down from $7.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $24.6 million in Q2 2025 to a low of $4.6 million in Q1 2021.
  • Historically, Operating Expenses has averaged $8.8 million across 5 years, with a median of $8.0 million in 2022.
  • Biggest five-year swings in Operating Expenses: soared 211.06% in 2021 and later tumbled 42.18% in 2025.
  • Year by year, Operating Expenses stood at $9.2 million in 2021, then crashed by 37.57% to $5.7 million in 2022, then surged by 46.49% to $8.4 million in 2023, then rose by 12.61% to $9.5 million in 2024, then tumbled by 42.18% to $5.5 million in 2025.
  • Business Quant data shows Operating Expenses for INMB at $5.5 million in Q4 2025, $7.4 million in Q3 2025, and $24.6 million in Q2 2025.